Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527551 | 1.00 | NOD2 (0.34) | NOD2NOD1DPP4MAPTALDH1A1 | |
| SCHEMBL25263110 | 0.90 | DPP4 (0.33) | DPP4ALDH1A1NR1H2NR1H3 | |
| SCHEMBL25887665 | 0.90 | DPP4 (0.31) | DPP4 | |
| SCHEMBL25299659 | 0.85 | NOD2 (0.37) | NOD2NOD1DPP4MAPTALDH1A1 | |
| SCHEMBL30527567 | 0.85 | NOD2 (0.37) | NOD2NOD1DPP4MAPTALDH1A1 | |
| SCHEMBL25308522 | 0.82 | NOD2 (0.40) | NOD2NOD1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL31250412 | 0.82 | NOD2 (0.40) | NOD2NOD1MAPTALDH1A1HTT | |
| SCHEMBL22468625 | 0.82 | NOD2 (0.40) | NOD2NOD1MAPTALDH1A1HTT | |
| SCHEMBL5065658 | 0.76 | NOD2 (0.47) | NOD2NOD1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL21685569 | 0.76 | NOD2 (0.45) | NOD2NOD1MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | NOD2 1645/4885NOD1 2047/4885DPP4 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.